StoxGlaxosmithkline Pharmaceuticals vs Emcure Pharmaceuticals: share price & financials comparison
NSE: GLAXO vs EMCURE · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Glaxosmithkline Pharmaceuticals vs Emcure Pharmaceuticals at a glance
Glaxosmithkline Pharmaceuticals (GLAXO) has a market capitalisation of ₹42,773 Cr, against ₹41,979 Cr for Emcure Pharmaceuticals (EMCURE). Over the past year Emcure Pharmaceuticals has returned +65.2%, compared with -4.5% for Glaxosmithkline Pharmaceuticals. On valuation, Emcure Pharmaceuticals trades at a lower P/E of 38.4 versus 83.0. Glaxosmithkline Pharmaceuticals earns a higher return on equity (27.4% vs 20.5%). Glaxosmithkline Pharmaceuticals comes out ahead on size and profitability. Emcure Pharmaceuticals comes out ahead on valuation, growth, momentum and technicals. Across the scored metrics below, Glaxosmithkline Pharmaceuticals leads on 5 and Emcure Pharmaceuticals on 7. On StoxGud's 10-point checklist, Glaxosmithkline Pharmaceuticals scores 7/10 and Emcure Pharmaceuticals scores 9/10.
| Metric | Glaxosmithkline Pharmaceuticals | Emcure Pharmaceuticals |
|---|---|---|
| Size | ||
| Market cap | ₹42,773 Cr | ₹41,979 Cr |
| Revenue (latest FY) | ₹3,822 Cr | ₹9,204 Cr |
| Net profit (latest FY) | ₹1,036 Cr | ₹924 Cr |
| Valuation | ||
| P/E | 83.0 | 38.4 |
| P/B | 22.74 | 7.86 |
| Dividend yield | 1.67% | 0.14% |
| Profitability | ||
| Return on equity | 27.4% | 20.5% |
| Net profit margin | 12.4% | 10.7% |
| Operating margin | 34.1% | 20.4% |
| Growth | ||
| Revenue growth (YoY) | +20.8% | +24.3% |
| Net profit growth (YoY) | — | +33.7% |
| Revenue CAGR (multi-year) | +2.9% | — |
| Financial health | ||
| Debt to equity | 0.00 | 0.27 |
| Momentum | ||
| 1-month return | -4.1% | +15.4% |
| 1-year return | -4.5% | +65.2% |
| 3-year CAGR | +20.8% | — |
| 5-year CAGR | +8.6% | — |
| 10-year CAGR | +6.1% | — |
| Distance from 52W high | -18.7% | -1.4% |
| Technicals | ||
| RSI (14) | 46 | 81 |
| Price vs 200-day avg | +0.3% | +27.3% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Glaxosmithkline Pharmaceuticals | Emcure Pharmaceuticals |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✗ | ✓ |
| Return on equity above 15% | ✓ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 7/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Glaxosmithkline Pharmaceuticals or Emcure Pharmaceuticals?
Glaxosmithkline Pharmaceuticals has a market cap of ₹42,773 Cr and Emcure Pharmaceuticals has a market cap of ₹41,979 Cr as of 06 Nov 2026.
Which has a lower P/E, Glaxosmithkline Pharmaceuticals or Emcure Pharmaceuticals?
Emcure Pharmaceuticals has the lower P/E: Glaxosmithkline Pharmaceuticals trades at 83.0 and Emcure Pharmaceuticals at 38.4.
Which gave better returns in the last year, Glaxosmithkline Pharmaceuticals or Emcure Pharmaceuticals?
Emcure Pharmaceuticals did better: Glaxosmithkline Pharmaceuticals returned -4.5% and Emcure Pharmaceuticals returned +65.2% over one year.
Is Glaxosmithkline Pharmaceuticals or Emcure Pharmaceuticals a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Glaxosmithkline Pharmaceuticals scores 7/10 and Emcure Pharmaceuticals scores 9/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.